Organization
Signifience, Biostatistics, Paris, France
3 abstracts
Abstract
ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTINGOrg: Bristol Myers Squibb, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, University of Leeds, University of Manchester and The Christie NHS Foundation Trust, Evangelical Hospital, Department of Internal Medicine, Vienna, Austria,
Abstract
ABSENCE OF ASSOCIATION BETWEEN ABATACEPT EXPOSURE LEVELS AND INITIAL INFECTION IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE RANDOMIZED, PLACEBO-CONTROLLED AVERT-2 STUDYOrg: University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, Leeds Teaching Hospitals NHS Trust, Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, University of Texas, Division of Rheumatology, Dallas, United States of America, Bristol Myers Squibb (at the time of analysis), Immunology and Fibrosis, Princeton, United States of America, Bristol Myers Squibb, Immunology and Fibrosis, Princeton, United States of America,
Abstract
ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIESOrg: Schlosspark-Klinik, University Medicine Berlin, Department of Internal Medicine, Rheumatology, Berlin, Germany, Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany, Bristol Myers Squibb, MESP France – Market Access, Rueil-Malmaison, France, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, Bristol Myers Squibb, Global Drug Development, Princeton, United States of America,